Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented a mathematical comparison of a "Staggered Start" and a "Randomized Withdrawal" clinical trial design with a "Natural History Staggered Start" clinical trial design at the Alzheimer's Association Prevention Conference held June 9 - 12, 2007, in Washington, D.C. The analysis demonstrates that the "Natural History Staggered Start" trial design currently being used in the Flurizan Phase 3 study can provide the same level of disease modification support as the cross-over trial designs, which are challenged by ethical concerns, dropout bias and complications.

A disease modifying therapy for Alzheimer's disease (AD) is one that has an impact on the underlying pathology of the disease and thus slows the rate of a patient's decline over the course of long-term treatment. In contrast, the currently available AD medicines are believed to treat the symptoms of AD without impacting the underlying disease process or providing long lasting benefit. The development of robust methods to demonstrate disease modification in AD clinical trials has been a controversial issue in the field, and to date, there have been no studies that provide convincing evidence of disease modification in AD. Two clinical trial designs that could provide evidence for disease modification were originally proposed for AD studies over 10 years ago by Paul Leber, then the head of the Division of Neuropharmacological Drug Products of the FDA. These designs have come to be known as the "Randomized Withdrawal" and "Staggered Start" designs and are based on measuring clinical outcomes in a cross-over type study.

In the randomized withdrawal design, patients are withdrawn from therapy after a defined period to determine whethe
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, ... Health Care Conference, New York, NY ... Accessing Live Webcasts To access the live webcasts ...
(Date:7/31/2014)... 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... its pipeline and new product development efforts. In the ... a Phase 2a study of AZ-002 (Staccato ® ... management of patients with acute repetitive seizures.  Additionally, ... product candidates for development - AZ-008 and AZ-009 ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) ... held on Friday, June 17, 2011. At the meeting, shareholders ... of incorporation to increase the total number of authorized shares ... About Cell Therapeutics, Inc. Headquartered in ...
... Pharmaceuticals, Inc. is initiating a voluntary recall of ... by Janssen Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and ... Patriot Pharmaceuticals, LLC, a wholly owned subsidiary of ... consumer reports of an uncharacteristic odor thought to ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 2Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 3Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 4Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 5Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 6Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets 7
(Date:7/31/2014)... 31, 2014 Leelanau Peninsula’s newest winery, ... 2014 at 7788 East Horn Road in Lake Leelanau. Joining ... , Aurora Cellars is the 25th winery along the trail. ... popular wine tour events, making its trail event debut during ... , Owners David and Faye Mathia opened the boutique ...
(Date:7/31/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
(Date:7/31/2014)... July 31, 2014 In many states and ... for proper storage of necessary life saving drugs. This requirement ... there is still a high number of ambulances without proper ... who steals the narcotics and even replaces the vital pain ... none. As seen in the case in Baraboo, Wisconsin last ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... In a comparison of anticoagulants and stents for use ... and tirofiban had similar outcomes for some cardiac measures ... received stents that released the drug sirolimus had a ... months than patients who received uncoated stents, according to ...
... March 29 The second annual,National Walk for ... and raised $1.5 million to help build awareness ... to raise much-needed funds. The event,was sponsored by ... http://www.newscom.com/cgi-bin/prnh/20080329/17897 ), The stars coming ...
... 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... the American College of Cardiology,s 57th Annual Scientific ... Among the most significant presentations are the following: ... Transplant Allograft Vasculopathy , Dr. Jeffrey ...
... room for improvement in balancing seizure control ... and medication-related side ... of the nation,s,largest event dedicated to the epilepsy community, ... in response to a,new national survey uncovering key challenges ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... Ranks above National Average in Overall Patient Satisfaction and Other ... ... The Hospital Quality Alliance today,released the first Hospital Consumer Assessment of ... care as rated by patients themselves. Hospital for Special Surgery,(HSS) in New ...
Cached Medicine News:Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:National Walk for Epilepsy Brings People and Celebrities Together for Epilepsy 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 2Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 3Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 4Health News:Leading Epilepsy Advocates Propose Strategies to Heighten Treatment Expectations and Close Patient and Physician Communication Gaps 5Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 2Health News:Hospital for Special Surgery Reports Scores on HCAHPS Survey 3
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: